All Stories

  1. Patents and the Global Diffusion of New Drugs
  2. The Economics of Reproducibility in Preclinical Research
  3. The Hidden Cost Of Low Prices: Limited Access To New Drugs In India
  4. Price indexes for clinical trial research: a feasibility study
  5. Why are some regions more innovative than others? The role of small firms in the presence of large labs
  6. Deals not done: Sources of failure in the market for ideas
  7. Deals Not Done: Sources of Failure in the Market for Ideas
  8. Price Indexes for Clinical Trial Research: A Feasibility Study
  9. Access to intellectual property for innovation: Evidence on problems and coping strategies from German firms
  10. Information Technology and Intangible Output: The Impact of IT Investment on Innovation Productivity
  11. Diffusion of New Drugs in the Post-TRIPS Era
  12. Entry and Patenting in the Software Industry
  13. Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases
  14. Patent thickets, licensing and innovative performance
  15. Patents and the survival of Internet-related IPOs
  16. Finding the Endless Frontier: Lessons from the Life Sciences Innovation System for Technology Policy
  17. Not Invented Here? Innovation in company towns
  18. Not Invented Here? Innovation in Company Towns
  19. Patents, Thickets and the Financing of Early-Stage Firms: Evidence from the Software Industry
  20. Faster, smaller, cheaper: an hedonic price analysis of PDAs
  21. Innovation in Global Industries
  22. Patent Thickets, Licensing and Innovative Performance
  23. Patents, Thickets, and the Financing of Early-Stage Firms: Evidence from the Software Industry
  24. Patents and the Survival of Internet-related IPOs
  25. National Bureau of Economic Research Patent Database: Audio of Presentation
  26. The Impact of Incremental Innovation in Biopharmaceuticals
  27. Entry and Patenting in the Software Industry
  28. Gone but not forgotten: knowledge flows, labor mobility, and enduring social relationships
  29. The Market For Follow-On Biologics: How Will It Evolve?
  30. Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research
  31. Faster, Smaller, Cheaper: An Hedonic Price Analysis of PDAs
  32. Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002
  33. The Changing Structure Of The Pharmaceutical Industry
  34. The anchor tenant hypothesis: exploring the role of large, local, R&D-intensive firms in regional innovation systems
  35. Gone But Not Forgotten: Labor Flows, Knowledge Spillovers, and Enduring Social Capital
  36. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998
  37. National trends in asthma visits and asthma pharmacotherapy, 1978-2002
  38. Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery
  39. O Brave New Industry, That Has Such Patents in It! Reflections on the Economic Consequences of Patenting DNA
  40. University Research, Industrial R&D, and the Anchor Tenant Hypothesis
  41. Are All Patent Examiners Equal? The Impact of Examiner Characteristics
  42. Measuring Competence? Exploring Firm Effects in Drug Discovery
  43. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
  44. New Pills for Poor People? Empirical Evidence after GATT
  45. Do Patents Matter?: Empirical Evidence after GATT
  46. Untangling the origins of competitive advantage
  47. Loss of Work Productivity due to Illness and Medical Treatment
  48. The Diffusion of Science-Driven Drug Discovery: Organizational Change in Pharmaceutical Research
  49. Balancing Incentives: The Tension Between Basic and Applied Research
  50. Hedonic Analysis of Arthritis Drugs
  51. Analysis of Patent Data: A Mixed-Poisson-Regression-Model Approach
  52. Public-Private Interaction and the Productivity of Pharmaceutical Research
  53. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins
  54. Public–private interaction in pharmaceutical research
  55. Mixed Poisson Regression Models with Covariate Dependent Rates
  56. Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
  57. Opportunity costs and entrepreneurial activity
  58. Racing To Invest? The Dynamics of Competition in Ethical Drug Discovery
  59. Measuring Competence? Exploring Firm Effects in Pharmaceutical Research
  60. Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
  61. Generics and New Goods in Pharmaceutical Price Indexes
  62. Market Conditions and Retirement of Physical Capital: Evidence fron Oil Tankers
  63. Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents
  64. Explaining the price of arthritis drugs
  65. Finding the Endless Frontier
  66. DO FIRMS CHANGE CAPABILITIES BY HIRING NEW PEOPLE? A STUDY OF THE ADOPTION OF SCIENCE-BASED DRUG DISCOVERY